ADMA Biologics, Inc.
ADMANASDAQHealthcareBiotechnology

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Company Information

CEOAdam Grossman
Founded2004
Employees685
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone201 478 5552
Address
465 State Route 17 Ramsey, New Jersey 07446 United States

Corporate Identifiers

CIK0001368514
CUSIP000899104
ISINUS0008991046
EIN56-2590442
SIC2836

Leadership Team & Key Executives

Adam S. Grossman
Co-Founder, President, Chief Executive Officer and Director
Dr. Jerrold B. Grossman D.P.S., Ph.D.
Co-Founder and Vice Chairman of the Board
Brad Tade
Chief Financial Officer and Treasurer
Kaitlin Kestenberg
Chief Operating Officer and Senior Vice President of Compliance
Michael Goldstein
General Counsel
John Hafl
Executive Director of Sales
Skyler Bloom
Senior Director of Business Development and Corporate Strategy